LumiraDx Limited Warrant (LMDXW)
$0.00
$0.00
(-47.69%)
As on 08-Jan-2024 18:31EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LumiraDx Limited Warrant (LMDXW)
| -60.5 | -61.8 | -87.1 | -96.2 | -- | -- | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -7.8 | 3.9 | 5.1 | 10.0 |
|
Company
|
2023
|
|---|---|
|
LumiraDx Limited Warrant (LMDXW)
| -85.4 |
|
BSE Sensex
| 18.7 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout LumiraDx Limited Warrant (LMDXW)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic... platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. Read more
-
CEO, Co-Founder & Chairman
Mr. Ron Zwanziger
-
CEO, Co-Founder & Chairman
Mr. Ron Zwanziger
-
Headquarters
London
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for LumiraDx Limited Warrant (LMDXW)
What is the current share price of LumiraDx Limited Warrant (LMDXW) Today?
The share price of LumiraDx Limited Warrant (LMDXW) is $0.00 (NASDAQ) as of 08-Jan-2024 18:31 EDT. LumiraDx Limited Warrant (LMDXW) has given a return of -96.22% in the last 1 years.
What is the current PB & PE ratio of LumiraDx Limited Warrant (LMDXW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.04 |
-0.17 |
2021 |
-4.54 |
2.81 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2022 |
-0.04 |
-0.17 |
What is the 52 Week High and Low of LumiraDx Limited Warrant (LMDXW)?
The 52-week high and low of LumiraDx Limited Warrant (LMDXW) are Rs -- and Rs -- as of 10-Sep-2026.
What is the market cap of LumiraDx Limited Warrant (LMDXW)?
LumiraDx Limited Warrant (LMDXW) has a market capitalisation of -- as on 25-Jan-2024. As per SEBI classification, it is a company.
Should I invest in LumiraDx Limited Warrant (LMDXW)?
Before investing in LumiraDx Limited Warrant (LMDXW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.